Chapter 4 : Cryptococcosis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Cryptococcosis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817879/9781555812607_Chap04-1.gif /docserver/preview/fulltext/10.1128/9781555817879/9781555812607_Chap04-2.gif


In patients with recognizable disease, the symptoms of pulmonary cryptococcosis may be mild and are typically chronic. It is likely that both reactivation of previous infection and primary progressive infection can cause CNS cryptococcosis in patients with AIDS. Given the frequent lack of inflammatory responses in patients with cryptococcosis and the possibility of enhancing the immune response by adjuvant type therapy, the factors involved in regulating the production of TH1 immunity to infection have received a great deal of study. Natural killer (NK) cells are also important in promoting the development of TH1 cells from naive TH cells during pulmonary cryptococcosis, primarily via the production of IFN- γ. Administration of IL-12 to wild-type mice enhances IFN- production, promotes clearance of , and prevents dissemination to the brain. In this study, pulmonary cryptococcosis was associated with almost no expression of TH1 mRNAs, but some TH2 mRNAs. Production of TNF-α in mice with pulmonary cryptococcosis occurs early during infection and also appears necessary for the development of protective TH1 immunity and macrophage activation. Nevertheless, neutralization of either MCP1 or MIP-1α in mice with pulmonary cryptococcosis results in reduced macrophage and leukocyte recruitment and impaired fungal clearance. Since control of cryptococcosis is associated with strong granulomatous responses, immune therapeutic approaches have focused on measures that stimulate cellular-mediated immunity.

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

India ink stain of CSF from rat with experimental meningitis. Note large capsules of organisms.

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

(A) Granulomatous inflammation in the meninges of rat with experimental cryptococcal meningitis. Arrows point to iNOS-expressing cells. (B) Rat lung, 1 year after pulmonary infection with (mucin stain). Lung contains small granulomatous foci with organisms. (C) Lung from NOS2 mouse infected with Intense granulomatous inflammation is present. Arrow points to (Photo courtesy of J. Rivera.) (D) Lung from wild-type (parental) mouse infected with A large number of organisms are present and form collections that distend alveoli. Minimal organized inflammation is present. (Photo courtesy of J. Rivera.)

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Abe, K.,, J. Kadota,, Y. Ishimatsu,, T. Iwashita,, K. Tomono,, K. Kawakami,, and S. Kohno. 2000. Th1-Th2 cytokine kinetics in the bronchoalveolar lavage fluid of mice infected with Cryptococcus neoformans of different virulences. Microbiol. Immunol. 44: 849 855.
2. Aguirre, K. M.,, and G. W. Gibson. 2000. Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection. Med. Mycol. 38: 343 353.
3. Allende, M.,, P. A. Pizzo,, M. Horowitz,, H. I. Pass,, and T. J. Walsh. 1993. Pulmonary cryptococcosis presenting as metastases in children with sarcomas. Pediatr. Infect. Dis. J. 12: 240 243.
4. Almeida, G. M.,, R. M. Andrade,, and C. A. Bento. 2001. The capsular polysaccharides of Cryptococcus neoformans activate normal CD4(+) T cells in a dominant Th2 pattern. J. Immunol. 167: 5845 5851.
5. Banerjee, U.,, K. Datta,, T. Majumdar,, and K. Gupta. 2001. Cryptococcosis in India: the awakening of a giant? Med. Mycol. 39: 51 67.
6. Blackstock, R. 1996. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol. 34: 19 30.
7. Blackstock, R.,, K. L. Buchanan,, A. M. Adesina,, and J. W. Murphy. 1999. Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect. Immun. 67: 3601 3609.
8. Blackstock, R.,, N. K. Hall,, and N. C. Hernandez. 1989. Characterization of a suppressor factor that regulates phagocytosis by macrophages in murine cryptococcosis. Infect. Immun. 57: 1773 1779.
9. Blackstock, R.,, N. McElwee,, E. Neller,, and J. Shaddix-White. 2000. Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12. Infect. Immun. 68: 5146 5153.
10. Bunting, L. A.,, J. B. Neilson,, and G. S. Bulmer. 1979. Cryptococcus neoformans: gastronomic delight of a soil ameba. Sabouraudia 17: 225 232.
11. Campbell, G. D. 1966. Primary pulmonary cryptococcosis. Am. Rev. Respir. Dis. 94: 236 243.
12. Casadevall, A.,, W. Cleare,, M. Feldmesser,, A. Glatman-Freedman,, D. L. Goldman,, T. R. Kozel,, N. Lendevai,, J. Mukherjee,, L.-A. Pirofski,, J. Rivera,, A. L. Rosas,, M. D. Scharff,, P. Valadon,, K. Westin,, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is candidate for human therapeutic studies. Infect. Immun. 42: 1437 1446.
13. Casadevall, A.,, A. L. Rosas,, and J. D. Nosanchuk. 2000. Melanin and virulence in Cryptococcus neoformans. Curr. Opin Microbiol. 3: 354 358.
14. Cauley, L. K.,, and J. W. Murphy. 1979. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect. Immun. 23: 644 651.
15. Chaka, W.,, R. Heyderman,, I. Gangaidzo,, V. Robertson,, P. Mason,, J. Verhoef,, A. Verheul,, and A. I. Hoepelman, and the University of Zimbabwe Meningitis Group. 1997. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis: no leukocytosis despite high interleukin- 8 levels. J. Infect. Dis. 176: 1633 1636.
16. Chaka, W.,, A. F. Verheul,, and A. I. Hoepelman. 1997. Influence of different condition on kinetics of tumor necrosis factor alpha release by peripheral blood mononuclear cells after stimulation with Cryptococcus neoformans: a possible explanation for different results. Clin. Diagn. Lab. Immunol. 4: 792 794.
17. Chaka, W.,, A. F. Verheul,, V. V. Vaishnav,, R. Cherniak,, J. Scharringa,, J. Verhoef,, H. Snippe,, and I. M. Hoepelman. 1997. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect. Immun. 65: 272 278.
18. Chiapello, L.,, P. Iribarren,, L. Cervi,, H. Rubinstein,, and D. T. Masih. 2001. Mechanisms for induction of immunosuppression during experimental cryptococcosis: role of glucuronoxylomannan. Clin. Immunol. 100: 96 106.
19. Cinti, S. K.,, W. S. Armstrong,, and C. A. Kauffman. 2001. Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis. Mycoses 44: 497 501.
20. Clemons, K. V.,, J. E. Lutz,, and D. A. Stevens. 2001. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob. Agents Chemother. 45: 686 689.
21. Coenjaerts, F. E.,, A. M. Walenkamp,, P. N. Mwinzi,, J. Scharringa,, H. A. Dekker,, J. A. van Strijp,, R. Cherniak,, and A. I. Hoepelman. 2001. Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J. Immunol. 167: 3988 3995.
22. Collins, H. L.,, and G. J. Bancroft. 1991. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun. 59: 3883 3888.
23. Cox, G. M.,, J. Mukherjee,, G. T. Cole,, A. Casadevall,, and J. R. Perfect. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect. Immun. 68: 443 448.
24. Currie, B. P.,, and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19: 1029 1033.
25. Del Poeta, M.,, D. L. Toffaletti,, T. H. Rude,, S. D. Sparks,, J. Heitman,, and J. R. Perfect. 1999. Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein. Infect. Immun. 67: 1812 1820.
26. DeShaw, M.,, and L.-A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals. Clin. Exp. Immunol. 99: 425 432.
27. Dong, Z. M.,, L. Jackson,, and J. W. Murphy. 1999. Mechanisms for induction of Lselectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan. Infect. Immun. 67: 220 229.
28. Dong, Z. M.,, and J. W. Murphy. 1996. Cryptococcal polysaccharide induces L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J. Clin. Investig. 97: 689 698.
29. Dong, Z. M.,, and J. W. Murphy. 1997. Cryptococcal polysaccharide binds to CD18 on human neutrophils. Infect. Immun. 65: 557 563.
30. Dromer, F.,, and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti- Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163: 1114 1120.
31. Facchetti, F.,, W. Vermi,, S. Fiorentini,, M. Chilosi,, A. Caruso,, M. Duse,, L. D. Notarangelo,, and R. Badolato. 1999. Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Am. J. Pathol. 154: 145 152.
32. Feldmesser, M.,, and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol. 158: 790 799.
33. Feldmesser, M.,, Y. Kress,, and A. Casadevall. 1998. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J. Infect. Dis. 177: 1639 1646.
34. Feldmesser, M.,, Y. Kress,, P. Novikoff,, and A. Casadevall. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68: 4225 4237.
35. Feldmesser, M.,, J. Mukherjee,, and A. Casadevall. 1996. Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro. J. Antimicrob Chemother. 37: 617 622.
36. Flesch, I. E.,, G. Schwamberger,, and S. H. Kaufmann. 1989. Fungicidal activity of IFNgamma- activated macrophages. Extracellular killing of Cryptococcus neoformans. J. Immunol. 142: 3219 3224.
37. Fleuridor, R.,, R. H. Lyles,, and L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180: 1526 1535.
38. Garcia-Hermoso, D.,, G. Janbon,, and F. Dromer. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37: 3204 3209.
39. Goldman, D.,, Y. Cho,, M.-L. Zhao,, A. Casadevall,, and S. C. Lee. 1996. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am. J. Pathol. 148: 1275 1282.
40. Goldman, D.,, X. Song,, R. Kitai,, A. Casadevall,, M.-L. Zhao,, and S. C. Lee. 2001. Cryptococcus neoformans induces macrophage inflammatory protein 1α (MIP-1α) and MIP- 1β in human microglia: role of specific antibody and soluble capsular polysaccharide. Infect. Immun. 69: 1808 1815.
41. Goldman, D. L.,, A. Casadevall,, Y. Cho,, and S. C. Lee. 1996. Cryptococcus neoformans meningitis in the rat. Lab. Invest. 75: 759 770.
42. Goldman, D. L.,, B. C. Fries,, S. P. Franzot,, L. Montella,, and A. Casadevall. 1998. Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc. Nat. Acad. Sci. USA 95: 14967 14972.
43. Goldman, D. L.,, H. Khine,, J. Abadi,, D. J. Lindenberg,, L.-A. Pirofski,, R. Niang,, and A. Casadevall. 2001. Serologic evidence for cryptococcus neoformans infection in early childhood. Pediatrics 107: e66. [Online.]
44. Goldman, D. L.,, S. C. Lee,, A. J. Mednick,, L. Montella,, and A. Casadevall. 2000. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression and al tered antibody responsiveness to cryptococcal polysaccharide. Infect. Immun. 68: 832 838.
45. Gordon, M. A.,, and A. Casadevall. 1995. Serum therapy of cryptococcal meningitis. Clin. Infect. Dis. 21: 1477 1479.
46. Gordon, M. A.,, and E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114: 373 378.
47. Graybill, J. R.,, L. Mitchell,, and D. J. Drutz. 1979. Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation. J. Infect. Dis. 140: 546 552.
48. Gyetko, M. R.,, G. H. Chen,, R. A. McDonald,, R. Goodman,, G. B. Huffnagle,, C. C. Wilkinson,, J. A. Fuller,, and G. B. Toews. 1996. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J. Clin. Investig. 97: 1818 1826.
49. Gyetko, M. R.,, S. Sud,, G. H. Chen,, J. A. Fuller,, S. W. Chensue,, and G. B. Toews. 2002. Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J. Immunol. 168: 801 809.
50. Hamilton, A. J.,, and M. D. Holdom. 1999. Antioxidant systems in the pathogenic fungi of man and their role in virulence. Med. Mycol. 37: 375 389.
51. Harrison, T. S.,, and S. M. Levitz. 1996. Role of IL-12 in peripheral blood mononuclear cell responses to fungi in persons with and without HIV infection. J. Immunol. 156: 4492 4497.
52. Haugen, R. K.,, and R. D. Baker. 1954. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am. J. Clin. Pathol. 24: 1381 1390.
53. Herring, A. C.,, J. Lee,, R. A. McDonald,, G. B. Toews,, and G. B. Huffnagle. 2002. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect. Immun. 70: 2959 2964.
54. Hidore, M. R.,, N. Nabavi,, F. Sonleitner,, and J. W. Murphy. 1991. Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect. Immun. 59: 1747 1754.
55. Hoag, K. A.,, M. F. Lipscomb,, A. A. Izzo,, and N. E. Street. 1997. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am. J. Respir. Cell Mol. Biol. 17: 733 739.
56. Hoag, K. A.,, N. E. Street,, G. B. Huffnagle,, and M. F. Lipscomb. 1995. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell Mol. Biol. 13: 487 495.
57. Huffnagle, G. B.,, G. H. Chen,, J. L. Curtis,, R. A. McDonald,, R. M. Strieter,, and G. B. Toews. 1995. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J. Immunol. 155: 3507 3516.
58. Huffnagle, G. B.,, M. F. Lipscomb,, J. A. Lovchick,, K. A. Hoag,, and N. E. Street. 1994. The role of CD4 +and CD8 +T-cells in protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55: 35 42.
59. Huffnagle, G. B.,, L. K. McNeil,, R. A. McDonald,, J. W. Murphy,, G. B. Toews,, M. Nobuyo,, and W. Kuziel. 1999. Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J. Immunol. 163: 4642 4646.
60. Huffnagle, G. B.,, N. E. Street,, and M. Lipscomb. 1992. In contrast to Balb/c mice, a Cryptococcus neoformans infection in C57BL/6 mice generates protective T cell immunity in the periphery and non-protective T-cell mediated eosinophilia in the lungs. FASEB J. 6: A1689.
61. Huffnagle, G. B.,, R. M. Strieter,, L. K. McNeil,, R. A. McDonald,, M. D. Burdick,, S. L. Kunkel,, and G. B. Toews. 1997. Macrophage inflammatory protein-1 α (MIP-1α) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J. Immunol. 159: 318 327.
62. Huffnagle, G. B.,, R. M. Strieter,, T. J. Standiford,, R. A. McDonald,, M. D. Burdick,, S. L. Kunkel,, and G. B. Toews. 1995. The role of monocyte chemotactic protein-1 (MCP- 1) in the recruitment of monocytes and CD4 + T cells during a pulmonary Cryptococcus neoformans infection. J. Immunol. 155: 4790 4797.
63. Huffnagle, G. B.,, G. B. Toews,, M. D. Burdick,, M. B. Boyd,, K. S. McAllister,, R. A. McDonald,, S. L. Kunkel,, and R. M. Strieter. 1996. Afferent phase production of TNFalpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J. Immunol. 157: 4529 4536.
64. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59: 1423 1433.
65. Jacobson, E. S. 2000. Pathogenic roles for fungal melanins. Clin. Microbiol. Rev. 13: 708 717.
66. Joly, V.,, L. Saint-Julien,, C. Carbon,, and P. Yeni. 1994. In vivo activity of interferongamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J. Infect. Dis. 170: 1331 1334.
67. Kanj, S. S.,, K. Welty-Woolf,, J. Madden,, V. Tapson,, M. A. Baez,, R. D. Davis,, and J. R. Perfect. 1996. Fungal infections in lung and heart-lung transplant recipients. Medicine 75: 142 156.
68. Kaplan, J. E.,, D. Hanson,, M. S. Dworkin,, T. Frederick,, J. Bertolli,, M. L. Lindegren,, S. Holmberg,, and J. L. Jones. 2000. Epidemiology of human immunodeficiency virusassociated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30( Suppl. 1): S5 S14.
69. Kawakami, K.,, Y. Kinjo,, S. Yara,, Y. Koguchi,, K. Uezu,, T. Nakayama,, M. Taniguchi,, and A. Saito. 2001. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69: 213 220.
70. Kawakami, K.,, Y. Koguchi,, M. H. Qureshi,, A. Miyazato,, S. Yara,, Y. Kinjo,, Y. Iwakura,, K. Takeda,, S. Akira,, M. Kurimoto,, and A. Saito. 2000. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. J. Immunol. 165: 941 947.
71. Kawakami, K.,, Y. Koguchi,, M. H. Qureshi,, S. Yara,, Y. Kinjo,, K. Uezu,, and A. Saito. 2000. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18. Microbiol. Immunol. 44: 1043 1050.
72. Kawakami, K.,, X. Qifeng,, M. Tohyama,, M. H. Qureshi,, and A. Saito. 1996. Contribution of tumour necrosis factor-alpha (TNF-alpha) in host defence mechanism against Cryptococcus neoformans. Clin. Exp. Immunol. 106: 468 474.
73. Kawakami, K.,, M. H. Qureshi,, T. Zhang,, H. Okamura,, M. Kurimoto,, and A. Saito. 1997. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J. Immunol. 159: 5528 5534.
74. Kawakami, K.,, M. Tohyama,, K. Teruya,, N. Kudeken,, Q. Xie,, and A. Saito. 1996. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 13: 123 130.
75. Kawakami, K.,, M. Tohyama,, Q. Xie,, and A. Saito. 1996. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin. Exp. Immunol. 104: 208 214.
76. Kawakami, K.,, T. Zhang,, M. H. Qureshi,, and A. Saito. 1997. Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-gamma and lipopolysaccharide. Cell. Immunol. 180: 47 54.
77. Kerkering, T. M.,, R. J. Duma,, and S. Shadomy. 1981. The evolution of pulmonary cryptococcosis. Ann. Intern. Med. 94: 611 616.
78. Lee, S. C.,, D. W. Dickson,, C. F. Brosnan,, and A. Casadevall. 1994. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J. Exp. Med. 180: 365 369.
79. Lee, S. C.,, D. W. Dickson,, and A. Casadevall. 1996. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathonenetic implications. Hum. Pathol. 27: 839 847.
80. Legendre, U.,, M. Battegay,, I. Nuttli,, P. Dalquen,, and R. Nuesch. 2001. Simultaneous occurrence of 2 HIV-related immunereconstitution diseases after initiation of highly active antiretroviral therapy. Scand. J. Infect. Dis. 33: 388 389.
81. Lendvai, N.,, X. W. Qu,, W. Hsueh,, and A. Casadevall. 2000. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J. Immunol. 164: 4367 4374.
82. Levitz, S. M.,, M. P. Dupont,, and E. H. Smail. 1994. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect. Immun. 62: 194 202.
83. Levitz, S. M.,, E. A. North,, Y. Jiang,, S. H. Nong,, and H. Kornfeld. 1997. Variables affecting production of monocyte chemotactic factor 1 from human leukocytes stimulated with Cryptococcus neoformans. Infect. Immun. 65: 903 908.
84. Levitz, S. M.,, A. Tabuni,, H. Kornfeld,, C. C. Reardon,, and D. T. Golenbock. 1994. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect. Immun. 62: 1975 1981.
85. Lim, T. S.,, and J. W. Murphy. 1980. Transfer of immunity to cryptococcosis by Tenriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30: 5 11.
86. Lipovsky, M. M.,, G. Gekker,, S. Hu,, L. C. Ehrlich,, A. I. Hoepelman,, and P. K. Peterson. 1998. Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8. J. Infect. Dis. 177: 260 263.
87. Lipovsky, M. M.,, L. Tsenova,, F. E. Coenjaerts,, G. Kaplan,, R. Cherniak,, and A. I. Hoepelman. 2000. Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis. J. Neuroimmunol. 111: 10 14.
88. Lipscomb, M. F.,, T. Alvarellos,, G. B. Tows,, R. Tompkins,, Z. Evans,, G. Koo,, and V. Kumar. 1987. Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am. J. Pathol. 128: 354 361.
89. Littman, M. L.,, and R. Borok. 1968. Relation of the pigeon to cryptococcosis: natural carrier state, heat resistance and survival of Cryptococcus neoformans. Mycopathol. Mycol. Appl. 35: 329 345.
90. Lovchik, J. A.,, C. R. Lyons,, and M. F. Lipscomb. 1995. A role for gamma interferoninduced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am. J. Respir. Cell Mol. Biol. 13: 116 124.
91. Lovchik, J. A.,, J. A. Wilder,, G. B. Huffnagle,, R. Riblet,, C. R. Lyons,, and M. F. Lipscomb. 1999. Ig heavy chain complex-linked genes influence the immune response in a murine cryptococcal infection. J. Immunol. 163: 3907 3913.
92. Lutz, J. E.,, K. V. Clemons,, and D. A. Stevens. 2000. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J. Antimicrob. Chemother. 46: 437 442.
93. Macher, A. M.,, J. E. Bennett,, J. E. Gadek,, and M. M. Frank. 1978. Complement depletion in cryptococcal sepsis. J. Immunol. 120: 1686 1690.
94. Merkel, G. J.,, and B. A. Scofield. 2000. The effects of Cryptococcus neoformans-secreted antigens on tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression on human lung epithelial cells. FEMS Immunol. Med. Microbiol. 29: 329 332.
95. Mody, C. H.,, M. F. Lipscomb,, N. E. Street,, and G. B. Tows. 1990. Depletion of CD4 + (L3T4 +) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J.Immunol. 144: 1472 1477.
96. Mody, C. H.,, C. L. Tyler,, R. G. Sitrin,, C. Jackson,, and G. B. Toews. 1991. Interferongamma activates rat alveolar macrophages for anticryptococcal activity. Am. J. Respir. Cell Mol. Biol. 5: 19 26.
97. Monari, C.,, T. R. Kozel,, A. Casadevall,, D. Pietrella,, B. Palazzetti,, and A. Vecchiarelli. 1999. B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology 98: 27 35.
98. Mukherjee, J.,, M. Feldmesser,, M. D. Scharff,, and A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob. Agents Chemother. 39: 1398 1405.
99. Mukherjee, J.,, L. Zuckier,, M. D. Scharff,, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with Amphotericin B. Antimicrob. Agents Chemother. 38: 580 587.
100. Murphy, J. W.,, and J. W. Moorhead. 1982. Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J. Immunol. 128: 276 283.
101. Murphy, J. W.,, R. L. Mosley,, and J. W. Moorhead. 1983. Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells. J. Immunol. 130: 2876 2881.
102. Naslund, P. K.,, W. C. Miller,, and D. L. Granger. 1995. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect. Immun. 63: 1298 1304.
103. Nosanchuk, J. D.,, A. L. Rosas,, and A. Casadevall. 1998. The antibody response to fungal melanin in mice. J. Immunol. 160: 6026 6031.
104. Nosanchuk, J. D.,, S. Shoham,, B. C. Fries,, D. S. Shapiro,, S. M. Levitz,, and A. Casadevall. 2000. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann. Intern. Med. 132: 205 208.
105. Noverr, M. C.,, S. M. Phare,, G. B. Toews,, M. J. Coffey,, and G. B. Huffnagle. 2001. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69: 2957 2963.
106. Olszewski, M. A.,, G. B. Huffnagle,, T. R. Traynor,, R. A. McDonald,, D. N. Cook,, and G. B. Toews. 2001. Regulatory effects of macrophage inflammatory protein 1α/CCL3 on the development of immunity to Cryptococcus neoformans depend on the expression of early inflammatory cytokines. Infect. Immun. 69: 6256 6263.
107. Pancharoen, C.,, A. Chindamporn,, and U. Thisyakorn. 2001. Childhood cryptococcosis: an increasing problem in the era of AIDS. J. Med. Assoc. Thai 84 ( Suppl.1): S86 S90.
108. Perfect, J. R.,, S. D. R. Lang,, and D. T. Durack. 1980. Chronic cryptococcal meningitis. Am. J. Pathol. 101: 177 193.
109. Pietrella, D.,, C. Monari,, C. Retini,, B. Palazzetti,, T. R. Kozel,, and A. Vecchiarelli. 1998. Cryptococcus neoformans and Candida albicans regulate CD4 expression on human monocytes. J. Infect. Dis. 178: 1464 1471.
110. Reardon, C. C.,, S. J. Kim,, R. P. Wagner,, and H. Kornfeld. 1996. Interferon-gamma reduces the capacity of human alveolar macrophages to inhibit growth of Cryptococcus neoformans in vitro. Am. J. Respir. Cell Mol. Biol. 15: 711 715.
111. Retini, C.,, A. Vecchiarelli,, C. Monari,, F. Bistoni,, and T. R. Kozel. 1998. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun. 66: 664 669.
112. Retini, C.,, A. Vecchiarelli,, C. Monari,, C. Tascini,, F. Bistoni,, and T. R. Kozel. 1996. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64: 2897 2903.
113. Rivera, J.,, J. Mukherjee,, L. M. Weiss,, and A. Casadevall. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168: 3419 3427.
114. Rosas, A. L.,, R. S. MacGill,, J. D. Nosanchuk,, T. R. Kozel,, and A. Casadevall. 2002. Activation of the alternative complement pathway by fungal melanins. Clin. Diagn. Lab. Immunol. 9: 144 148.
115. Rosas, A. L.,, J. D. Nosanchuk,, M. Feldmesser,, G. M. Cox,, H. C. McDade,, and A. Casadevall. 2000. Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect. Immun. 68: 2845 2853.
116. Rossi, G. R.,, L. A. Cervi,, M. M. Garcia,, L. S. Chiapello,, D. A. Sastre,, and D. T. Masih. 1999. Involvement of nitric oxide in protecting mechanism during experimental cryptococcosis. Clin. Immunol. 90: 256 265.
117. Salkowski, C. A.,, and E. Balish. 1991. A monoclonal antibody to gamma interferon blocks augmentation of natural killer cell activity induced during systemic cryptococcosis. Infect. Immun. 59: 486 493.
118. Scrimgeour, E. M.,, and R. G. Purohit. 1984. Chronic pulmonary cryptococcosis in a Rattus rattus from Raboul, Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 78: 827 828.
119. Shahar, A.,, Y. Kletter,, and M. Aronson. 1969. Granuloma formation in cryptococcosis. Israel. J. Med. Sci. 5: 1164 1172.
120. Shoham, S.,, C. Huang,, J. M. Chen,, D. T. Golenbock,, and S. M. Levitz. 2001. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166: 4620 4626.
121. Steenbergen, J. N.,, H. A. Shuman,, and A. Casadevall. 2001. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl. Acad. Sci. USA 98: 15245 15250.
122. Syme, R. M.,, T. F. Bruno,, T. R. Kozel,, and C. H. Mody. 1999. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect. Immun. 67: 4620 4627.
123. Traynor, T. R.,, A. C. Herring,, M. E. Dorf,, W. A. Kuziel,, G. B. Toews,, and G. B. Huffnagle. 2002. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J. Immunol. 168: 4659 4666.
124. Tucker, S. C.,, and A. Casadevall. 2002. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99: 3165 3170.
125. Vecchiarelli, A.,, and A. Casadevall. 1998. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res. Immunol. 149: 321 333.
126. Vecchiarelli, A.,, C. Monari,, C. Retini,, D. Pietrella,, B. Palazzetti,, L. Pitzura,, and A. Casadevall. 1998. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7- 2 (CD86) expression on human monocytes. Eur. J. Immunol. 28: 114 121.
127. Vecchiarelli, A.,, D. Pietrella,, M. Dottorini,, C. Monari,, C. Retini,, and T. Todisco. 1995. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98: 217 223.
128. Vecchiarelli, A.,, C. Retini,, C. Monari,, F. Bistoni,, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64: 2846 2849.
129. Vecchiarelli, A.,, C. Retini,, C. Monari,, and A. Casadevall. 1998. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes Tcell proliferation. Infect. Immun. 66: 1244 1247.
130. Vecchiarelli, A.,, C. Retini,, D. Pietrella,, C. Monari,, C. Tascini,, T. Beccari,, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1beta secretion from human monocytes. Infect. Immun. 63: 2919 2923.
131. Woods, M. L.,, R. MacGinley,, D. P. Eisen,, and A. M. Allworth. 1998. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 12: 1491 1494.
132. Yuan, R.,, A. Casadevall,, J. Oh,, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify C. neoformans infections in mice. Proc. Natl. Acad. Sci. USA 94: 2483 2488.
133. Zhang, T.,, K. Kawakami,, M. H. Qureshi,, H. Okamura,, M. Kurimoto,, and A. Saito. 1997. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect. Immun. 65: 3594 3599.


Generic image for table
Table 1

Activities of capsular polysaccharides that affect immune response

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error